Production of Long-Acting CNGRC–CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment
Objectives: Aminopeptidase N (APN) is an enzyme highly expressed in metastatic cancers and could be used in targeted cancer therapy. Our previous work showed the successful construction of CNGRC–carboxypeptidase G2 (CPG2) and CNGRC–CPG2–CNGRC fusion proteins. Our conjugates and prodrugs were effecti...
Enregistré dans:
Auteurs principaux: | Layla Al-mansoori, Alanod D. Al Qahtani, Philip Elsinga, Sayed K. Goda |
---|---|
Format: | article |
Langue: | EN |
Publié: |
SAGE Publishing
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/358b31bcd3b34e60a2416e17aedd761e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
par: Layla Al-mansoori, et autres
Publié: (2021) -
Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation
par: Ibrahim IM, et autres
Publié: (2019) -
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance
par: Xiaoguang Li, et autres
Publié: (2019) -
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
par: James J. Hobson, et autres
Publié: (2019) -
Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein
par: Michael B. Battles, et autres
Publié: (2017)